Sutro Biopharma Inc (NASDAQ: STRO) is -1.17% lower on its value in year-to-date trading and has touched a low of $2.01 and a high of $6.13 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The STRO stock was last observed hovering at around $4.39 in the last trading session, with the day’s loss setting it -0.15%.
Currently trading at $4.24, the stock is -2.91% and -6.92% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.23 million and changing -3.42% at the moment leaves the stock 4.95% off its SMA200. STRO registered -1.85% loss for a year compared to 6-month gain of 10.70%. The firm has a 50-day simple moving average (SMA 50) of -$0.11 and a 200-day simple moving average (SMA200) of $0.29.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -4.93% loss in the last 1 month and extending the period to 3 months gives it a 5.21%, and is -16.70% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.80% over the week and 11.07% over the month.
Sutro Biopharma Inc (STRO) has around 302 employees, a market worth around $326.14M and $153.73M in sales. Profit margin for the company is -69.47%. Distance from 52-week low is 111.47% and -30.83% from its 52-week high. The company has generated returns on investments over the last 12 months (-33.17%).
Sutro Biopharma Inc quarterly earnings per share for the current quarter are estimated at -$0.92 with sales reaching $11.92M over the same period.The EPS is expected to shrink by -101.38% this year, but quarterly earnings will post -63.70% year-over-year. Quarterly sales are estimated to shrink -5.90% in year-over-year returns.
164 institutions hold shares in Sutro Biopharma Inc (STRO), with institutional investors hold 96.36% of the company’s shares. The shares outstanding are 76.92M, and float is at 73.71M with Short Float at 3.27%. Institutions hold 95.25% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 5.82 million shares valued at $24.69 million. The investor’s holdings represent 9.33% of the STRO Shares outstanding. As of Dec 30, 2023, the second largest holder is Suvretta Capital Management, LLC with 5.78 million shares valued at $24.5 million to account for 9.25% of the shares outstanding. The other top investors are Adage Capital Partners GP L.L.C. which holds 4.47 million shares representing 7.16% and valued at over $18.94 million, while Rubric Capital Management LP holds 5.36% of the shares totaling 3.34 million with a market value of $14.18 million.
Sutro Biopharma Inc (STRO) Insider Activity
The most recent transaction is an insider sale by Vasquez Nicki, the company’s CHIEF PORT. STRAT & ALNCE OFCR. SEC filings show that Vasquez Nicki sold 12,185 shares of the company’s common stock on Jan 29 ’24 at a price of $5.00 per share for a total of $60925.0. Following the sale, the insider now owns 12803.0 shares.
Sutro Biopharma Inc disclosed in a document filed with the SEC on Aug 28 ’23 that Shtylla Brunilda (Chief Business Officer) sold a total of 15,428 shares of the company’s common stock. The trade occurred on Aug 28 ’23 and was made at $4.71 per share for $72595.0. Following the transaction, the insider now directly holds 0.0 shares of the STRO stock.
Still, SEC filings show that on Aug 25 ’23, Shtylla Brunilda (Chief Business Officer) disposed off 11,613 shares at an average price of $4.59 for $53282.0. The insider now directly holds 12,928 shares of Sutro Biopharma Inc (STRO).
